Advice

Advice

NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer because no evidence submission was received from Roche for the technology.

  • National Institute for Health and Care Excellence (NICE)